{"entity":{"id":"pd-32766","kind":"drug","name":"225Ac/64Cu-PD-32766 (CA9 theranostic pair)","aka":["PD-32766","225Ac-PD-32766","64Cu-PD-32766","PD-32766T","PD-32766D"],"tldr":"225Ac/64Cu-PD-32766 (CA9 theranostic pair) is an experimental radioligand peptide-drug conjugate, theranostic pair from PeptiDream, in phase 1 trials for clear cell renal cell carcinoma.","summary":"225Ac/64Cu-PD-32766 (CA9 theranostic pair) (PD-32766, 225Ac-PD-32766, 64Cu-PD-32766) is a radioligand peptide-drug conjugate (RI-PDC), theranostic pair from PeptiDream. A peptide-radioisotope conjugate against carbonic anhydrase IX (CAIX), a tumour-associated antigen highly expressed in clear cell renal cell carcinoma; the copper-64 version is for PET imaging and the actinium-225 version is the treatment. Its furthest stage is phase 1, for clear cell renal cell carcinoma. ClinicalTrials.gov registers it in one study linked below. PeptiDream's pipeline table still says IND-enabling, but the same page says the FDA cleared the IND, and NCT07688187 (sponsor PeptiDream Inc.) is recruiting per the v2 API. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"PeptiDream: peptidream.com","url":"https://www.peptidream.com/en/pipeline/"},{"label":"PeptiDream: peptidream.com","url":"https://www.peptidream.com/en/pipeline/"},{"label":"PeptiDream: peptidream.com","url":"https://www.peptidream.com/en/pipeline/"},{"label":"PeptiDream: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07688187"},{"label":"ClinicalTrials.gov: trials of PD-32766","url":"https://clinicaltrials.gov/search?intr=PD-32766"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["clear-cell-rcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["peptidream"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07688187"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"PD-32766","modality":"Radioligand peptide-drug conjugate (RI-PDC), theranostic pair","mechanism":"A peptide-radioisotope conjugate against carbonic anhydrase IX (CAIX), a tumour-associated antigen highly expressed in clear cell renal cell carcinoma; the copper-64 version is for PET imaging and the actinium-225 version is the treatment.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pd-32766/","neighbours":{"cancer":[{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/"}],"company":[{"id":"peptidream","kind":"company","name":"PeptiDream","route":"/companies/peptidream/"}],"trial":[{"id":"nct07688187","kind":"trial","name":"A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma","route":"/trials/nct07688187/"}]}}